相似文献
1
Editorial of Special Column on RNA Therapeutics and Drug Delivery Technologies for Medical Applications.
Acta Pharm Sin B. 2023 Apr;13(4):1346-1347. doi: 10.1016/j.apsb.2023.03.005. Epub 2023 Mar 8.
2
Editor Profile: Guest Editor of Special Column on RNA Therapeutics and Drug Delivery Technologies for Medical Applications.
Acta Pharm Sin B. 2023 Apr;13(4):1345. doi: 10.1016/j.apsb.2023.03.006. Epub 2023 Apr 19.
3
An introduction to RNA therapeutics and their potentials.
Prog Mol Biol Transl Sci. 2024;203:1-12. doi: 10.1016/bs.pmbts.2023.12.020. Epub 2024 Jan 25.
4
The development and technologies of RNA therapeutics.
Prog Mol Biol Transl Sci. 2024;203:13-39. doi: 10.1016/bs.pmbts.2023.12.017. Epub 2024 Jan 6.
5
Editorial of Special Column "Research on Emerging COVID-19 (Target, Mechanism, and Therapeutics)".
Acta Pharm Sin B. 2020 Jul;10(7):1146-1148. doi: 10.1016/j.apsb.2020.07.009. Epub 2020 Aug 18.
6
Solid Lipid Nanoparticles: Applications and Prospects in Cancer Treatment.
Int J Mol Sci. 2023 Mar 24;24(7):6199. doi: 10.3390/ijms24076199.
7
Editorial of Special Issue "Surface-Functionalized Nanoparticles as Drug Carriers".
Int J Mol Sci. 2019 Dec 17;20(24):6352. doi: 10.3390/ijms20246352.
8
Lipid nanoparticles (LNPs) for in vivo RNA delivery and their breakthrough technology for future applications.
Adv Drug Deliv Rev. 2023 Sep;200:114990. doi: 10.1016/j.addr.2023.114990. Epub 2023 Jul 7.
9
Editorial of Special Column on A New Era of Nanobiomaterial-based Drug Delivery.
Acta Pharm Sin B. 2022 Sep;12(9):3453-3455. doi: 10.1016/j.apsb.2022.08.002. Epub 2022 Sep 20.
10
Editorial for the Special Issue on "Nucleic Acid Architectures for Therapeutics, Diagnostics, Devices and Materials".
Nanomaterials (Basel). 2019 Jun 30;9(7):951. doi: 10.3390/nano9070951.
本文引用的文献
1
Doxorubicin-conjugated siRNA lipid nanoparticles for combination cancer therapy.
Acta Pharm Sin B. 2023 Apr;13(4):1429-1437. doi: 10.1016/j.apsb.2022.07.011. Epub 2022 Jul 21.
2
Targeted delivery of RNAi to cancer cells using RNA-ligand displaying exosome.
Acta Pharm Sin B. 2023 Apr;13(4):1383-1399. doi: 10.1016/j.apsb.2022.11.019. Epub 2022 Nov 17.
3
Recent progress of aptamer‒drug conjugates in cancer therapy.
Acta Pharm Sin B. 2023 Apr;13(4):1358-1370. doi: 10.1016/j.apsb.2023.01.017. Epub 2023 Jan 26.
4
Progress in non-viral localized delivery of siRNA therapeutics for pulmonary diseases.
Acta Pharm Sin B. 2023 Apr;13(4):1400-1428. doi: 10.1016/j.apsb.2022.07.010. Epub 2022 Jul 19.
5
mRNA delivery in cancer immunotherapy.
Acta Pharm Sin B. 2023 Apr;13(4):1348-1357. doi: 10.1016/j.apsb.2023.03.001. Epub 2023 Mar 5.
6
The tumor therapeutic potential of long non-coding RNA delivery and targeting.
Acta Pharm Sin B. 2023 Apr;13(4):1371-1382. doi: 10.1016/j.apsb.2022.12.005. Epub 2022 Dec 13.
7
Nucleic acid nanoassembly-enhanced RNA therapeutics and diagnosis.
Acta Pharm Sin B. 2023 Mar;13(3):916-941. doi: 10.1016/j.apsb.2022.10.019. Epub 2022 Oct 27.
8
Lipid nanomaterials-based RNA therapy and cancer treatment.
Acta Pharm Sin B. 2023 Mar;13(3):903-915. doi: 10.1016/j.apsb.2022.10.004. Epub 2022 Oct 11.
9
Sodium alginate coating simultaneously increases the biosafety and immunotherapeutic activity of the cationic mRNA nanovaccine.
Acta Pharm Sin B. 2023 Mar;13(3):942-954. doi: 10.1016/j.apsb.2022.08.015. Epub 2022 Aug 27.
10
Concurrent silencing of TBCE and drug delivery to overcome platinum-based resistance in liver cancer.
Acta Pharm Sin B. 2023 Mar;13(3):967-981. doi: 10.1016/j.apsb.2022.03.003. Epub 2022 Mar 12.
Zotero 插件